Compare $ENSC vs $VTGN | Chartloom

Compare

$ENSC vs $VTGN

Ensysce Biosciences Inc · Vistagen Therapeutics Inc

ENSC

Ensysce Biosciences Inc

VTGN

Vistagen Therapeutics Inc

Compare $ENSC vs $VTGN

Comparing Ensysce Biosciences Inc and Vistagen Therapeutics Inc

ENSCEnsysce Biosciences Inc

VTGNVistagen Therapeutics Inc

ENSCEnsysce Biosciences Inc

Market cap

$8M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

-39.3%

YTD performance

-43.9%

52W performance

-78.6%

FCF yield

-116.0%

VTGNVistagen Therapeutics Inc

Market cap

$10M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

278.5%

YTD performance

-65.2%

52W performance

-94.1%

FCF yield

-644.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ENSC

VTGN

Detailed metrics comparison

ENSC

Ensysce Biosciences Inc

VTGN

Vistagen Therapeutics Inc

Market Cap

ENSC$8M

VTGN$10M

Enterprise Value

ENSC$7M

VTGN$-7M

Price

ENSC$0.53

VTGN$0.24

P/E Ratio

ENSCN/A

VTGNN/A

P/S Ratio

ENSC1.72x

VTGN3.87x

EV/Sales

ENSC1.61x

VTGN-2.92x

EV/EBITDA

ENSC0.00x

VTGN0.00x

P/B Ratio

ENSC2.39x

VTGN0.56x

P/FCF Ratio

ENSCN/A

VTGNN/A

EV/FCF

ENSC-0.81x

VTGN0.12x

PEG Ratio

ENSCN/A

VTGNN/A

Forward P/E (NTM)

ENSCN/A

VTGNN/A

Forward P/S (NTM)

ENSCN/A

VTGNN/A

Revenue (TTM)

ENSC$5M

VTGN$3M

Revenue Growth (YoY)

ENSC-39.3%

VTGN278.5%

Forward Rev Growth

ENSC-45.7%

VTGN4633.2%

Gross Margin (TTM)

ENSC0.0%

VTGN0.0%

Operating Margin (TTM)

ENSC0.0%

VTGN0.0%

EBITDA Margin (TTM)

ENSC-197.8%

VTGN-2775.9%

Net Margin (TTM)

ENSC-280.5%

VTGN-2702.6%

FCF Margin (TTM)

ENSC-199.5%

VTGN-2493.3%

Net Income (TTM)

ENSC$-13M

VTGN$-68M

FCF (TTM)

ENSC$-9M

VTGN$-62M

EPS (TTM)

ENSC-$0.97

VTGN-$1.57

ROE (TTM)

ENSC-37496.0%

VTGN-15259.0%

ROA (TTM)

ENSC-32046.0%

VTGN-11745.0%

ROIC (TTM)

ENSC-33277.0%

VTGN-15162.0%

Cash

ENSC$677K

VTGN$17M

Debt

ENSC$197K

VTGN$0

Net Cash/Debt

ENSC$480K

VTGN$17M

Current Ratio (TTM)

ENSC0.70x

VTGN3.07x

Quick Ratio (TTM)

ENSC0.37x

VTGN2.84x

Debt/Equity (TTM)

ENSC0.10x

VTGN0.00x

Debt/Assets (TTM)

ENSC0.0%

VTGN0.0%

Interest Coverage (TTM)

ENSCN/A

VTGNN/A

Net Debt/EBITDA (TTM)

ENSC0.00x

VTGN0.00x

Beta

ENSC1.10

VTGN0.49

52W Performance

ENSC-78.6%

VTGN-94.1%

YTD Performance

ENSC-43.9%

VTGN-65.2%

% from 52W High

ENSC-80.8%

VTGN-95.4%

% from 52W Low

ENSC129.1%

VTGN19.2%

Asset Turnover (TTM)

ENSC1.14x

VTGN0.04x

FCF Yield (TTM)

ENSC-116.0%

VTGN-644.0%

Earnings Yield (TTM)

ENSC-163.1%

VTGN-698.0%

Dividend Yield (TTM)

ENSCN/A

VTGNN/A

Rule of 40

ENSC-238.8

VTGN-2,214.8

EV/GP/RG

ENSCN/A

VTGNN/A

Ticker research

View ENSC research View VTGN research

Metric	ENSC Ensysce Biosciences Inc	VTGN Vistagen Therapeutics Inc
Market & Valuation
Market Cap	$8M	$10M
Enterprise Value	$7M	$-7M
Price	$0.53	$0.24
P/E Ratio	N/A	N/A
P/S Ratio	1.72x	3.87x
EV/Sales	1.61x	-2.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.39x	0.56x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.81x	0.12x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$5M	$3M
Revenue Growth (YoY)	-39.3%	278.5%
Forward Rev Growth	-45.7%	4633.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-197.8%	-2775.9%
Net Margin (TTM)	-280.5%	-2702.6%
FCF Margin (TTM)	-199.5%	-2493.3%
Net Income (TTM)	$-13M	$-68M
FCF (TTM)	$-9M	$-62M
EPS (TTM)	-$0.97	-$1.57
ROE (TTM)	-37496.0%	-15259.0%
ROA (TTM)	-32046.0%	-11745.0%
ROIC (TTM)	-33277.0%	-15162.0%
Financial Health
Cash	$677K	$17M
Debt	$197K	$0
Net Cash/Debt	$480K	$17M
Current Ratio (TTM)	0.70x	3.07x
Quick Ratio (TTM)	0.37x	2.84x
Debt/Equity (TTM)	0.10x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.10	0.49
52W Performance	-78.6%	-94.1%
YTD Performance	-43.9%	-65.2%
% from 52W High	-80.8%	-95.4%
% from 52W Low	129.1%	19.2%
Efficiency & Yields
Asset Turnover (TTM)	1.14x	0.04x
FCF Yield (TTM)	-116.0%	-644.0%
Earnings Yield (TTM)	-163.1%	-698.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-238.8	-2,214.8
EV/GP/RG	N/A	N/A
Ticker research	View ENSC research	View VTGN research

Valuation

P/S Ratio

ENSC

1.72x

VTGN

3.87x

EV/FCF

ENSC

-0.81x

VTGN

0.12x

Growth & revenue

Revenue Growth TTM

VTGN

278.5%

ENSC

-39.3%

Forward Revenue Growth

VTGN

4633.2%

ENSC

-45.7%

Profitability & performance

Gross Margin

ENSC

0.0%

VTGN

0.0%

ROE

VTGN

-15259.0%

ENSC

-37496.0%

FCF Yield %

ENSC

-116.0%

VTGN

-644.0%

52-Week Performance

ENSC

-78.6%

VTGN

-94.1%

Detailed metrics comparison

ENSC

Ensysce Biosciences Inc

VTGN

Vistagen Therapeutics Inc

Market Cap

ENSC$8M

VTGN$10M

Enterprise Value

ENSC$7M

VTGN$-7M

Price

ENSC$0.53

VTGN$0.24

P/E Ratio

ENSCN/A

VTGNN/A

P/S Ratio

ENSC1.72x

VTGN3.87x

EV/Sales

ENSC1.61x

VTGN-2.92x

EV/EBITDA

ENSC0.00x

VTGN0.00x

P/B Ratio

ENSC2.39x

VTGN0.56x

P/FCF Ratio

ENSCN/A

VTGNN/A

EV/FCF

ENSC-0.81x

VTGN0.12x

PEG Ratio

ENSCN/A

VTGNN/A

Forward P/E (NTM)

ENSCN/A

VTGNN/A

Forward P/S (NTM)

ENSCN/A

VTGNN/A

Revenue (TTM)

ENSC$5M

VTGN$3M

Revenue Growth (YoY)

ENSC-39.3%

VTGN278.5%

Forward Rev Growth

ENSC-45.7%

VTGN4633.2%

Gross Margin (TTM)

ENSC0.0%

VTGN0.0%

Operating Margin (TTM)

ENSC0.0%

VTGN0.0%

EBITDA Margin (TTM)

ENSC-197.8%

VTGN-2775.9%

Net Margin (TTM)

ENSC-280.5%

VTGN-2702.6%

FCF Margin (TTM)

ENSC-199.5%

VTGN-2493.3%

Net Income (TTM)

ENSC$-13M

VTGN$-68M

FCF (TTM)

ENSC$-9M

VTGN$-62M

EPS (TTM)

ENSC-$0.97

VTGN-$1.57

ROE (TTM)

ENSC-37496.0%

VTGN-15259.0%

ROA (TTM)

ENSC-32046.0%

VTGN-11745.0%

ROIC (TTM)

ENSC-33277.0%

VTGN-15162.0%

Cash

ENSC$677K

VTGN$17M

Debt

ENSC$197K

VTGN$0

Net Cash/Debt

ENSC$480K

VTGN$17M

Current Ratio (TTM)

ENSC0.70x

VTGN3.07x

Quick Ratio (TTM)

ENSC0.37x

VTGN2.84x

Debt/Equity (TTM)

ENSC0.10x

VTGN0.00x

Debt/Assets (TTM)

ENSC0.0%

VTGN0.0%

Interest Coverage (TTM)

ENSCN/A

VTGNN/A

Net Debt/EBITDA (TTM)

ENSC0.00x

VTGN0.00x

Beta

ENSC1.10

VTGN0.49

52W Performance

ENSC-78.6%

VTGN-94.1%

YTD Performance

ENSC-43.9%

VTGN-65.2%

% from 52W High

ENSC-80.8%

VTGN-95.4%

% from 52W Low

ENSC129.1%

VTGN19.2%

Asset Turnover (TTM)

ENSC1.14x

VTGN0.04x

FCF Yield (TTM)

ENSC-116.0%

VTGN-644.0%

Earnings Yield (TTM)

ENSC-163.1%

VTGN-698.0%

Dividend Yield (TTM)

ENSCN/A

VTGNN/A

Rule of 40

ENSC-238.8

VTGN-2,214.8

EV/GP/RG

ENSCN/A

VTGNN/A

Ticker research

View ENSC research View VTGN research

Metric	ENSC Ensysce Biosciences Inc	VTGN Vistagen Therapeutics Inc
Market & Valuation
Market Cap	$8M	$10M
Enterprise Value	$7M	$-7M
Price	$0.53	$0.24
P/E Ratio	N/A	N/A
P/S Ratio	1.72x	3.87x
EV/Sales	1.61x	-2.92x
EV/EBITDA	0.00x	0.00x
P/B Ratio	2.39x	0.56x
P/FCF Ratio	N/A	N/A
EV/FCF	-0.81x	0.12x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$5M	$3M
Revenue Growth (YoY)	-39.3%	278.5%
Forward Rev Growth	-45.7%	4633.2%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-197.8%	-2775.9%
Net Margin (TTM)	-280.5%	-2702.6%
FCF Margin (TTM)	-199.5%	-2493.3%
Net Income (TTM)	$-13M	$-68M
FCF (TTM)	$-9M	$-62M
EPS (TTM)	-$0.97	-$1.57
ROE (TTM)	-37496.0%	-15259.0%
ROA (TTM)	-32046.0%	-11745.0%
ROIC (TTM)	-33277.0%	-15162.0%
Financial Health
Cash	$677K	$17M
Debt	$197K	$0
Net Cash/Debt	$480K	$17M
Current Ratio (TTM)	0.70x	3.07x
Quick Ratio (TTM)	0.37x	2.84x
Debt/Equity (TTM)	0.10x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.10	0.49
52W Performance	-78.6%	-94.1%
YTD Performance	-43.9%	-65.2%
% from 52W High	-80.8%	-95.4%
% from 52W Low	129.1%	19.2%
Efficiency & Yields
Asset Turnover (TTM)	1.14x	0.04x
FCF Yield (TTM)	-116.0%	-644.0%
Earnings Yield (TTM)	-163.1%	-698.0%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-238.8	-2,214.8
EV/GP/RG	N/A	N/A
Ticker research	View ENSC research	View VTGN research